Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Palatin (PLTN) -- Ignore unavailable to you. Want to Upgrade?

To: cheech who wrote (21)	4/23/1998 2:20:00 PM
From: incomep	Read Replies (1) \| Respond to of 61

Anybody around? It is a solid company with small floats. Plus they have tow products. Anyone has idea of the mechanism of the oral peptide delivery system for erectile dysfunction? Hope it is not through liposome. Palatin Technologies Holds Annual Meeting PRINCETON, N.J.--(BW HealthWire)--March 25, 1998--Palatin Technologies (Nasdaq:PLTN - news) Wednesday announced that it held its Annual Meeting of Stockholders Tuesday, March 24, 1998, at 11 a.m., at the company's headquarters as scheduled. According to the announcement by Palatin Technologies Chairman President and Chief Executive Officer Edward J. Quilty, a quorum of stockholders was present in person or by proxy, and all proposals submitted to the stockholders were approved. The Directors elected were Edward J. Quilty, 46, chairman, president and chief executive officer of Palatin Technologies and also chairman of the board of Derma Sciences, a publicly traded company; Carl Spana, Ph.D., 35, Palatin's executive vice president and chief technology officer; Michael S. Weiss, 31, general counsel of Paramount Capital Investments and senior managing director of Paramount Capital Inc.; James T. O'Brien, 58, president and chief executive officer of O'Brien Marketing and Communications, an advertising and communications company; and John K.A. Prendergast, Ph.D., 43, president and principal of Summercloud Bay Inc., a biotechnology consulting firm. All these directors have double duty, what are they actually doing?